CUTR's GenesisPlus Laser Treatment Provides an Effective Option for Millions WorldwideOnychomycosis is commonly known as toenail fungus.
It is a chronic fungal infection affecting the toenails and fingernails of approximately 35 million patients in the U.S. alone. Only about 20% of these patients, or 7 million, seek professional care form a physician.
Clinical symptoms include yellow discoloration, thickening of the nail, subungual (under the nail) debris and loss of attachment of the nail plate to the nail bed. The global market for onychomycosis treatments was estimated to be over $2.0B in 2010.
** CUTR reported U.S. Food and Drug Administration (FDA) 510k clearance for its GenesisPlus. The complete list of the indications for use can be found in the FDA 510k clearance number (K) 103626.
GenesisPlus utilizes CUTR’s patented microsecond technology and features a proprietary delivery system with a temperature sensor to improve the practitioner and patient experience.
CUTR’s GenesisPlus laser is a great innovation in the treatment of fungal nails.
Current treatment options include prescription topicals and oral drugs, both with limited success rates. Some patients are not candidates for oral medications, due to concerns of liver damage and other treatment limitations—
CUTR’s GenesisPlus provides a fast and effective solution for onychomycosis, without the risks of serious side effects.
More about CUTR at http://www.cutera.com/
No comments:
Post a Comment